Resistance to single‐agent chemotherapy and its risk factors in low‐risk gestational trophoblastic neoplasms

Gestational trophoblastic neoplasm (GTN) is a rare disease which is classified into high‐ and low‐risk groups. While the high‐risk patients require combination therapy, the low‐risk groups respond to single‐agent chemotherapy. We studied resistance to single‐agent chemotherapy and its risk factors among the low‐risk GTN patients in Iran.

[1]  T. Lawrie,et al.  First-line chemotherapy in low-risk gestational trophoblastic neoplasia. , 2016, The Cochrane database of systematic reviews.

[2]  N. Sebire,et al.  Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009 , 2012, British Journal of Cancer.

[3]  E. Refaie,et al.  Chemo-resistant gestational trophoblastic neoplasia, 5-years experience of Mansoura University Hospital, Egypt , 2011 .

[4]  R. Berkowitz,et al.  Current Chemotherapeutic Management of Patients with Gestational Trophoblastic Neoplasia , 2011, Chemotherapy research and practice.

[5]  C. Aghajanian.  Treatment of low-risk gestational trophoblastic neoplasia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Provencher,et al.  Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Cho,et al.  Serum hCG Level and Rising World Health Organization Score at Second-Line Chemotherapy (Pulse Dactinomycin): Poor Prognostic Factors for Methotrexate-Failed Low-Risk Gestational Trophoblastic Neoplasia , 2010, International Journal of Gynecologic Cancer.

[8]  W. Kang,et al.  Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia. , 2010, Gynecologic oncology.

[9]  V. Fülöp,et al.  30 years' experience in the treatment of low-risk gestational trophoblastic neoplasia in Hungary. , 2010, The Journal of reproductive medicine.

[10]  M. Seckl,et al.  The management and outcome of women with post-hydatidiform mole ‘low-risk’ gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU l−1 , 2010, British Journal of Cancer.

[11]  G. Chalouhi,et al.  Methotrexate for 2000 FIGO low-risk gestational trophoblastic neoplasia patients: efficacy and toxicity. , 2009, American journal of obstetrics and gynecology.

[12]  Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia , 2009, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[13]  A. Sharifi,et al.  Pulse methotrexate versus pulse actinomycin D in the treatment of low‐risk gestational trophoblastic neoplasia , 2008, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[14]  A. Rademaker,et al.  Gestational Trophoblastic Neoplasia: Treatment Outcomes , 2008, Obstetrics and gynecology.

[15]  A. Schott,et al.  What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or low-risk metastatic gestational trophoblastic tumors? A review of the evidence. , 2006, Gynecologic oncology.

[16]  A. Leiser,et al.  Evaluation and management of gestational trophoblastic disease , 2006 .

[17]  J. Qian,et al.  [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof]. , 2005, Zhonghua yi xue za zhi.

[18]  P. Hanjani,et al.  Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low‐risk gestational trophoblastic neoplasia , 2005, The Australian & New Zealand journal of obstetrics & gynaecology.

[19]  J. Cardoza,et al.  Sonographic and Doppler Imaging in the Diagnosis and Treatment of Gestational Trophoblastic Disease , 2005, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[20]  H. Ngan.  The practicability of FIGO 2000 staging for gestational trophoblastic neoplasia. , 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[21]  B. Hancock.  Staging and classification of gestational trophoblastic disease. , 2003, Best practice & research. Clinical obstetrics & gynaecology.

[22]  I. McNeish,et al.  Doppler ultrasonography of the uterine artery and the response to chemotherapy in patients with gestational trophoblastic tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  E. Kohorn.  The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: Description and critical assessment , 2000, International Journal of Gynecologic Cancer.

[24]  B. Hancock,et al.  A retrospective comparison of current and proposed staging and scoring systems for persistent gestational trophoblastic disease. , 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[25]  Mohamed El-Shebiney,et al.  Treatment Outcome of Gestational Trophoblastic Neoplasia , 2012 .

[26]  Kim Jh,et al.  Changes in gestational trophoblastic tumors over four decades. A Korean experience. , 1998 .

[27]  J. H. Kim,et al.  Changes in gestational trophoblastic tumors over four decades. A Korean experience. , 1998, The Journal of reproductive medicine.